Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D02WSB
|
|||
| Former ID |
DNCL002675
|
|||
| Drug Name |
CRS-207
|
|||
| Drug Type |
Vaccine
|
|||
| Indication | Gastric adenocarcinoma [ICD-11: 2B72; ICD-9: 151] | Phase 2 | [1], [2] | |
| Mesothelioma [ICD-11: 2C51.2; ICD-10: C45; ICD-9: 163] | Phase 2 | [1], [2] | ||
| Pancreatic cancer [ICD-11: 2C10] | Phase 2 | [3] | ||
| Ovarian cancer [ICD-11: 2C73; ICD-10: C56; ICD-9: 183] | Phase 1/2 | [1], [2] | ||
| Company |
Aduro BioTech
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Mesothelin (MSLN) | Target Info | . | [4] |
| NetPath Pathway | TCR Signaling Pathway | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 3 | ClinicalTrials.gov (NCT02243371) GVAX Pancreas Vaccine (With CY) and CRS-207 With or Without Nivolumab. U.S. National Institutes of Health. | |||
| REF 4 | Safety and survival with GVAX pancreas prime and Listeria Monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer. J Clin Oncol. 2015 Apr 20;33(12):1325-33. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.